Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$0.34
-0.4%
$0.39
$0.30
$10.62
$45.30M1.823.44 million shs1.86 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$33.90
-1.3%
$33.28
$29.31
$61.38
$4.14B0.591.52 million shs1.30 million shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$1.23
+1.2%
$1.19
$0.66
$1.55
$281.85M1.861.46 million shs433,035 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$4.62
+0.2%
$4.97
$3.51
$16.95
$37.93M0.2476,706 shs36,017 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$8.77
-1.6%
$6.25
$2.21
$19.71
$622.74M0.451.55 million shs499,121 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
0.00%+4.08%-7.37%-22.51%-92.31%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
0.00%+2.23%+5.67%-9.26%-37.68%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
0.00%-2.00%-2.78%+53.13%+18.93%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
0.00%+5.24%+8.45%+19.69%-62.81%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
0.00%-10.01%+86.89%+79.61%-14.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
3.8147 of 5 stars
3.31.00.04.70.61.71.3
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
3.9341 of 5 stars
4.52.00.04.60.00.80.0
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.66 of 5 stars
3.51.00.04.71.51.70.0
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.8397 of 5 stars
3.51.00.04.60.62.50.6
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.6013 of 5 stars
4.51.00.00.01.15.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
2.50
Moderate Buy$6.101,710.09% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.93
Moderate Buy$70.92109.21% Upside
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.00
Buy$7.33498.64% Upside
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.00
Buy$43.20835.06% Upside
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.00
Buy$17.5099.66% Upside

Current Analyst Ratings Breakdown

Latest PHAT, APLT, KPTI, CYTK, and GOSS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $17.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
5/29/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.00
5/14/2025
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.50
5/14/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/13/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$265K180.04N/AN/A$0.49 per share0.69
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$18.47M219.20N/AN/A($1.15) per share-29.48
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$114.70M2.43N/AN/A$0.13 per share9.42
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$145.24M0.27N/AN/A($22.10) per share-0.21
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$55.25M11.07N/AN/A($3.71) per share-2.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$76.42M-$13.26N/AN/AN/A-43.99%N/A-35.95%8/5/2025 (Estimated)
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/6/2025 (Estimated)

Latest PHAT, APLT, KPTI, CYTK, and GOSS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million
5/12/2025Q1 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
4/14/2025Q4 2024
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/A
3.00
3.00
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
5.99
5.99
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70
5.71
5.71
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
1.33
1.28
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
3.58
3.54

Institutional Ownership

CompanyInstitutional Ownership
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
98.31%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
30141.58 million139.31 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million116.20 millionOptionable
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
180227.30 million212.07 millionOptionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3808.64 million8.38 millionOptionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11069.81 million53.76 millionOptionable

Recent News About These Companies

Phathom Pharmaceuticals, Inc. (PHAT) - Yahoo Finance
Phathom Pharmaceuticals Appoints Cook as Chief Legal Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Applied Therapeutics stock logo

Applied Therapeutics NASDAQ:APLT

$0.34 0.00 (-0.38%)
Closing price 07/3/2025 03:50 PM Eastern
Extended Trading
$0.34 0.00 (-0.30%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$33.90 -0.46 (-1.34%)
Closing price 07/3/2025 02:25 PM Eastern
Extended Trading
$34.52 +0.62 (+1.81%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Gossamer Bio stock logo

Gossamer Bio NASDAQ:GOSS

$1.23 +0.02 (+1.24%)
Closing price 07/3/2025 03:47 PM Eastern
Extended Trading
$1.23 0.00 (0.00%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$4.62 +0.01 (+0.22%)
Closing price 07/3/2025 02:45 PM Eastern
Extended Trading
$4.49 -0.13 (-2.81%)
As of 07/3/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$8.76 -0.15 (-1.63%)
Closing price 07/3/2025 03:47 PM Eastern
Extended Trading
$8.87 +0.10 (+1.20%)
As of 07/3/2025 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.